Sangamo Therapeutics, Inc.’s EPS Growth at a glance
Sangamo Therapeutics, Inc. reports eps growth of 66.9% for Dec 2024. The prior period recorded -18.4% (Dec 2023). Year over year the metric moved +85.3 pts (+463.5%). The rolling three-period average stands at 15.6%. Data last refreshed Dec 7, 2025, 2:52 AM.
Latest reading
66.9% · Dec 2024
YoY movement
+85.3 pts (+463.5%)
Rolling average
15.6%
Current EPS Growth
66.9%
+85.3 pts
+463.5%
Rolling average
15.6%
Latest Value
66.9%
Dec 2024
YoY Change
+85.3 pts
Absolute
YoY Change %
+463.5%
Rate of change
3-Period Avg
15.6%
Smoothed
Narrative signal
Sangamo Therapeutics, Inc.’s eps growth stands at 66.9% for Dec 2024. Year-over-year, the metric shifted by +85.3 pts, translating into a +463.5% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes Sangamo Therapeutics, Inc.'s story
As of Dec 2024, Sangamo Therapeutics, Inc. reports eps growth of 66.9%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
100%
Operating Margin
-179.9%
Net Profit Margin
-169.4%
Return on Equity
-430.1%
Return on Assets
-96.4%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Sangamo Therapeutics, Inc. (SGMO) FAQs
Answers tailored to Sangamo Therapeutics, Inc.’s eps growth profile using the latest Financial Modeling Prep data.
What is Sangamo Therapeutics, Inc.'s current eps growth?
As of Dec 2024, Sangamo Therapeutics, Inc. reports eps growth of 66.9%. This reading reflects the latest filings and price data for SGMO.
How is Sangamo Therapeutics, Inc.'s eps growth trending year over year?
Year-over-year, the figure shifts by +85.3 pts (+463.5%). Pair this context with revenue growth and free cash flow signals to gauge momentum for SGMO.
Why does eps growth matter for Sangamo Therapeutics, Inc.?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For Sangamo Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Sangamo Therapeutics, Inc.'s eps growth above its recent average?
Sangamo Therapeutics, Inc.'s rolling three-period average sits at 15.6%. Comparing the latest reading of 66.9% to that baseline highlights whether momentum is building or fading for SGMO.
How frequently is Sangamo Therapeutics, Inc.'s eps growth refreshed?
Data for SGMO was last refreshed on Dec 7, 2025, 2:52 AM and updates automatically every 24 hours, keeping your valuation inputs current.